Citicoline builds membranes (phosphatidylcholine) and raises dopamine. Alpha-GPC delivers choline faster and shows stronger acute effects on power output and reaction time. For cognitive aging, citicoline has the deeper trial base. For same-day mental performance, Alpha-GPC has the edge.
What each molecule actually is
Both compounds deliver choline to the brain, but through different routes with different downstream effects.
Citicoline (CDP-choline, sold as Cognizin) is broken down into cytidine and choline. The choline becomes phosphatidylcholine — the primary phospholipid in every neuronal membrane. The cytidine becomes uridine, which supports synaptic plasticity.
Alpha-GPC (L-alpha-glycerylphosphorylcholine) is a smaller molecule. It crosses the blood-brain barrier faster and directly raises acetylcholine — the neurotransmitter behind attention, learning, and muscle contraction.
Same starting material. Different mechanisms. Different use cases.
Head-to-head: what the trials show
| Endpoint | Citicoline (Cognizin) | Alpha-GPC |
|---|---|---|
| Acute choline delivery | Moderate — takes ~1 hr to peak | Fast — 30-60 min |
| Membrane synthesis (PC) | Strong — direct precursor | Weak — not a phospholipid pathway |
| Acetylcholine boost | Moderate | Strong |
| Human trial base | Deep (stroke, MCI, adolescent attention) | Moderate (dementia, athletic performance) |
| Best-studied dose | 250–500 mg/day | 300–600 mg/day |
| Onset for effects | Weeks (cumulative) | Acute (same-day) + cumulative |
| Price per gram | Higher (patented Cognizin) | Lower (generic widely available) |
The Silveri lab at McLean/MIT ran two citicoline trials worth knowing about. In healthy adolescent males, 250 or 500 mg daily for 28 days significantly improved attention and psychomotor speed on the Ruff 2 & 7 test.[1] In middle-aged women, 250 or 500 mg daily for 28 days improved attention on the Continuous Performance Test II.[2] Both trials were placebo-controlled.
Alpha-GPC's headline human trial is De Jesus Moreno Moreno 2003 — a 261-patient, double-blind, placebo-controlled study in mild-to-moderate Alzheimer's. Patients got 400 mg three times daily for 180 days. The Alpha-GPC group showed significant improvements on MMSE, ADAS-Cog, and Global Deterioration Scale versus placebo.[3]
The mechanism difference matters
If your goal is same-day cognitive performance — a hard meeting, a study session, a workout — Alpha-GPC has the acute pharmacology to deliver. It raises acetylcholine within an hour and shows measurable effects on reaction time and lower-body power output in trained subjects.[4]
If your goal is slow structural support — protecting neurons over years, supporting recovery after mild cognitive injury, or building a stack for age-related decline — citicoline's membrane synthesis story is stronger. You're literally providing raw material for phosphatidylcholine, which every neuron continuously replaces.
STRONG: Citicoline for cognitive aging and MCI (multiple large trials).MODERATE: Alpha-GPC for acute cognitive/athletic performance (smaller trial base).The Alpha-GPC stroke controversy
An Alpha-GPC caveat worth naming: a 2021 observational study using South Korean insurance data reported a higher stroke incidence in Alpha-GPC users versus non-users over 10 years.[5] The paper has real limitations — it's observational, users self-selected, and confounding by indication is likely (people with vascular risk factors are more likely to take a "brain supplement"). But if you have cardiovascular risk factors, citicoline is the more conservative pick until this signal is resolved in prospective trials.
What we'd actually stack
These two aren't mutually exclusive. Some cognitive stacks use Alpha-GPC before demanding tasks and citicoline daily for baseline support. That's a legitimate approach — different mechanisms, no redundancy.
If forced to pick one:
- Under 40, healthy, want acute focus: Alpha-GPC, 300–600 mg pre-task.
- 40+, thinking about the long game: citicoline (Cognizin), 250–500 mg daily.
- Vascular risk factors: citicoline. Skip Alpha-GPC until the stroke data is prospectively resolved.
- Post-concussion or MCI recovery: citicoline. The trial base for neuroprotection is deeper.
What to actually buy
Jarrow Formulas Citicoline (Cognizin)
Patented Cognizin form used in the McLean/MIT trials. 250 mg capsules — the low-end trial dose. Vegetarian, third-party tested.
Check Amazon price →Double Wood Alpha-GPC 300mg
Straightforward Alpha-GPC at the clinically studied 300 mg dose. Double Wood is one of the more transparent third-party-testing brands in the nootropics space.
Check Amazon price →Nutricost Citicoline
Generic citicoline (not branded Cognizin) at a significantly lower price per serving. Reasonable choice if cost is a constraint and you're taking it daily.
Check Amazon price →Citations
- McGlade E, et al. Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women. Food and Nutrition Sciences, 2012;3:769-773.
- Silveri MM, et al. Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR Biomed. 2008;21(10):1066-1075.
- De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003;25(1):178-193.
- Bellar D, et al. The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength. J Int Soc Sports Nutr. 2015;12:42.
- Lee G, et al. Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years. JAMA Netw Open. 2021;4(11):e2136008.
- Fioravanti M, Buckley AE. Citicoline (Cognizin) in the treatment of cognitive impairment. Clin Interv Aging. 2006;1(3):247-251.
- Parnetti L, et al. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? J Neurol Sci. 2007;257(1-2):264-269.